Royalty Pharma (RPRX)
Buys drug royalties and funds late-stage medicines for future royalty streams.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 63.11% | 362.91M shares | |
|---|---|---|---|
| 658 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 17.88% | 102.79M shares | |
| 13 holders · as of Aug 19, 2026 | |||
| Other | ≈ 19.01% | 109.30M shares | |
| remainder | |||
575.00M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (575.00M in the company's Sep 23, 2026 report, 443.27M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
This company has 2 share classes; every stake here is a share of the whole company.
13F, as of Jun 30, 2026
658 holders · 362.91M shares · 110 new positions · 407 increased · 174 reduced · 52 closed
| Holder | Shares | % of company | Chg q/q | Filed |
|---|---|---|---|---|
| Morgan Stanley | 42.93M | 7.47% | −640.0K | Aug 13, 2026 |
| Capital International Investors | 35.27M | 6.13% | +268.0K | Aug 12, 2026 |
| BlackRock, Inc. | 27.83M | 4.84% | +1.93M | Aug 7, 2026 |
| FMR LLC | 24.51M | 4.26% | −638.4K | Aug 13, 2026 |
| State Street Corp | 12.34M | 2.15% | +1.35M | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 11.19M | 1.95% | +9.26M | Aug 14, 2026 |
| Swedbank AB | 10.73M | 1.87% | −860.1K | Jul 15, 2026 |
| Baillie Gifford & Co | 10.02M | 1.74% | −6.14M | Aug 6, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Legorreta G. Pabloincl. Legorreta Investments, LLC | 18.73% | 101.79M | 13D | Aug 17, 2026 |
| Morgan Stanley | 9.20% | 38.91M | 13G | Aug 5, 2025 |
| Capital International Investors | 8.80% | 37.77M | 13G | May 14, 2026 |
| FMR LLC | 6.50% | 27.90M | 13G | Nov 5, 2025 |
| R & H Trust Co. (Guernsey) Limitedincl. Severgnini Achille G. | 5.70% | 24.22M | 13D | Feb 20, 2026 |
| BlackRock, Inc. | 5.70% | 25.45M | 13G | Feb 4, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Christopher Hiteofficer: EVP & Chairman, Partnering | Sale | 100,000 | $59.97 | 370,401 |
| Aug 13, 2026 | Terrance P. Coyneofficer: EVP & CFO | Sale · 2 lots | 11,002 | $58.68 | 0 |
| Jul 1, 2026 | Marshall Uristofficer: EVP, Research & Investments | Sale | 9,099 | $55.88 | 0 |
| Jun 23, 2026 | Christopher Hiteofficer: EVP & Chairman, Partnering | Sale · 2 lots | 150,000 | $54.40 | 559,399 |
| Jun 24, 2026 | Marshall Uristofficer: EVP, Research & Investments | Sale | 9,098 | $55.18 | 9,099 |
| May 26, 2026 | Terrance P. Coyneofficer: EVP & CFO | Sale | 64,399 | $53.98 | 0 |
| May 20, 2026 | Marshall Uristofficer: EVP, Research & Investments | Sale | 13,684 | $52.75 | 18,197 |
| May 14, 2026 | Gregory Nordendirector | Sale | 3,045 | $53.00 | 191,803 |
| May 14, 2026 | Marshall Uristofficer: EVP, Research & Investments | Sale | 13,684 | $53.06 | 31,881 |
| Apr 28, 2026 | Terrance P. Coyneofficer: EVP & CFO | Sale · 2 lots | 34,791 | $49.78 | 0 |
House and Senate disclosures
Not reported.